It is a polypeptide and highly specific direct thrombin antagonist whereas it shows no effect on antithrombin-III.
It is synthesized by recombinant DNA technology in yeast cells.
Mechanism of action:
One molecule of lepirudin gets bind to one molecule of thrombin causing stoppage of thrombogenic effect of thrombin.
It is administered intravenously.
It undergoes hydrolysis in the body. Its half life is 1 hour. Drug and its metabolites are excreted in the urine.
It is used effectively in the treatment of thrombocytopenia induced by heparin.
It is also used for other thromboembolic disorders and also causes stoppage of further thromboembolic complications.
It may cause bleeding. The drug forms complex with antibody in the body and anticoagulant effect may be elevated, than required, by the slower rate of excretion of the drug-antibody complex from the body.
It may also cause certain allergic reactions of the skin and air passages.